Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 10
Submit an article Journal homepage
59
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Transplantation provides superior survival high risk myeloid malignancies in older patients

Celalettin Ustuna Division of Hematology, Oncology and Cellular Therapy, Rush University, Chicago, IL, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6896-6213
ORCID Icon,
Erica Warlickb Syros Pharmaceuticals, Inc., Cambridge, MA, USA
,
Sunita Nathana Division of Hematology, Oncology and Cellular Therapy, Rush University, Chicago, IL, USA
,
Linda J. Burnsc Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA
&
Daniel Weisdorfd Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA
Pages 2494-2498 | Received 28 Feb 2022, Accepted 04 May 2022, Published online: 19 May 2022
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Disclosure statement

D.W., J.B., and S.N. have no relevant COI regarding this manuscript. E.W. UMOEN: Regional Oncology Pharmacy Conference: Paid Speaking Honorarium for lecture on the History of AML and new treatment updates. Currently Medical Director at Syros Pharmaceuticals and has stocks of the company. C.U. Honoria from blueprint for being in speaker bureau.

Figure 1. Disease-free survival in patients with MDS (A, reported by Nakamura et al. [Citation3]) and patients with AML (B, reported by Ustun et al. [Citation5]) is superior after allogeneic hematopoietic cell transplantation compared with no transplantation.

Figure 1. Disease-free survival in patients with MDS (A, reported by Nakamura et al. [Citation3]) and patients with AML (B, reported by Ustun et al. [Citation5]) is superior after allogeneic hematopoietic cell transplantation compared with no transplantation.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.